Evaluation of corneal cross-linking as adjuvant therapy for the management of fungal keratitis
- 69 Downloads
To evaluate the efficacy of corneal cross-linking (CXL) as adjuvant therapy for the treatment of fungal ulcerative keratitis.
Forty-one patients with fungal ulcerative keratitis were recruited and assigned into two randomized controlled groups. These groups were treated with CXL combined with antifungal medications (CXL-M) or antifungal medications alone (M). The ulcers were assessed by slit-lamp biomicroscopy, slit-lamp images, in vivo confocal microscopy (IVCM), and anterior segment optical coherence tomography (AS-OCT). The patients were followed up before surgery/first visit (FV), 1 day after surgery, 1 and 2 weeks, and 1, 2, 3, 4, 5, and 6 months after surgery/FV.
In the cured patients, the area of corneal ulcers, the duration of ulcer healing, the time to non-observed fungal hyphae by IVCM, the number of antifungal medications, the frequency of administered medications, and the maximum ulcer depth decreased significantly after CXL (all P < 0.05) compared with the M group. There were no significant differences in either corneal thickness or epithelial thickness of ulcers after healing between 5 and 6 months after surgery in the CXL-M group, while these were increased significantly at 6 months compared with 5 months after FV in the M group (both P < 0.05).
In our study, CXL accelerated healing of the fungal ulcers, shortened the treatment duration, and minimized the need for medications and surgery. It appears that CXL is an effective procedure and adjuvant therapy for managing fungal keratitis.
KeywordsCorneal cross-linking Fungal keratitis Riboflavin Ultraviolet A (UV-A)
This work was supported by grants from the National Natural Science Foundation of China (No. 81300759).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Prajna NV, Srinivasan M, Lalitha P, Krishnan T, Rajaraman R, Ravindran M, Mascarenhas J, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM (2013) Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol 131:1088–1089. https://doi.org/10.1001/jamaophthalmol.2013.1612 CrossRefGoogle Scholar
- 6.Martins SA, Combs JC, Noguera G, Camacho W, Wittmann P, Walther R, Cano M, Dick J, Behrens A (2008) Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 49:3402–3408. https://doi.org/10.1167/iovs.07-1592 CrossRefGoogle Scholar
- 11.Alhayek A, Lu PR (2015) Corneal collagen crosslinking in keratoconus and other eye disease. Int J Ophthalmol 8:407–418. https://doi.org/10.3980/j.issn.2222-3959.2015.02.35 Google Scholar
- 13.Li G, Fan ZJ, Peng XJ (2012) Corneal collagen crosslinking for corneal ectasia of post-LASIK: one-year results. Int J Ophthalmol 5:190–195. https://doi.org/10.3980/j.issn.2222-3959.2012.02.15 Google Scholar
- 15.Alshehri JM, Caballero-Lima D, Hillarby MC, Shawcross SG, Brahma A, Carley F, Read ND, Radhakrishnan H (2016) Evaluation of corneal cross-linking for treatment of fungal keratitis: using confocal laser scanning microscopy on an ex vivo human corneal model. Invest Ophthalmol Vis Sci 57:6367–6373. https://doi.org/10.1167/iovs.16-20110 CrossRefGoogle Scholar
- 16.Goodrich RP (2000) The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78(Suppl 2):211–215Google Scholar
- 26.Xie L, Zhai H, Shi W (2007) Penetrating keratoplasty for corneal perforations in fungal keratitis. Cornea 26:158–162. https://doi.org/10.1097/01.ico.0000248381.24519.0d CrossRefGoogle Scholar
- 27.Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW, Jr. (2012) Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg 28: 706–713 DOI https://doi.org/10.3928/1081597X-20120921-06
- 28.Ozdemir HB, Kalkanci A, Bilgihan K, Gocun PU, Ogut B, Karakurt F, Erdogan M (2018) Comparison of corneal collagen cross-linking (PACK-CXL) and voriconazole treatments in experimental fungal keratitis. Acta Ophthalmol. https://doi.org/10.1111/aos.13829
- 40.Mazzotta C, Balestrazzi A, Traversi C, Baiocchi S, Caporossi T, Tommasi C, Caporossi A (2007) Treatment of progressive keratoconus by riboflavin-UVA-induced cross-linking of corneal collagen: ultrastructural analysis by Heidelberg Retinal Tomograph II in vivo confocal microscopy in humans. Cornea 26:390–397. https://doi.org/10.1097/ICO.0b013e318030df5a CrossRefGoogle Scholar